<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693170</url>
  </required_header>
  <id_info>
    <org_study_id>W00090 GE 2 01</org_study_id>
    <nct_id>NCT03693170</nct_id>
  </id_info>
  <brief_title>Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer</brief_title>
  <acronym>ANCHOR-CRC</acronym>
  <official_title>Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of the combination of study&#xD;
      drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic&#xD;
      colorectal cancer and have not received any prior treatment for their metastatic disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The presence of a BRAFV600E mutation is considered a marker of poor prognosis in subjects&#xD;
      with mCRC. The preclinical results and preliminary clinical data together justify the&#xD;
      evaluation of this triple combination in the first-line setting of this population. The&#xD;
      primary objective of the study is to evaluate the antitumor activity of the combination of&#xD;
      encorafenib, binimetinib and cetuximab by assessing the overall response rate in adult&#xD;
      subjects with previously untreated BRAFV600E-mutant metastatic colorectal cancer. It will&#xD;
      also assess the effect of the triple combination on the duration of response, time to&#xD;
      response, progression-free survival and overall survival and assess the effect on quality of&#xD;
      life. It will also characterize the safety and tolerability of the triple combination as well&#xD;
      as describe the pharmacokinetics (PK) of encorafenib, binimetinib, and cetuximab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">December 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All involved know the identity of the intervention assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Overall Response Rate (cORR) based on local tumor assessments</measure>
    <time_frame>Duration of the study, approximately 25 months</time_frame>
    <description>Assessment of tumor evaluation change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed Overall Response Rate (cORR) based on central tumor assessment</measure>
    <time_frame>globally assessed by subject based on tumor evaluations every 6 weeks for the first 12 weeks and then every 8 weeks.</time_frame>
    <description>Percentage of subjects with complete response (CR) and partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response (ORR) based on local tumor assessments</measure>
    <time_frame>Globally assessed by subject based on tumor evaluations every 6 weeks for the first 12 weeks and then every 8 weeks.</time_frame>
    <description>Percentage of subjects with complete response (CR) and partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response (ORR) based on central tumor assessments</measure>
    <time_frame>Globally assessed by subject based on tumor evaluations every 6 weeks for the first 12 weeks and then every 8 weeks.</time_frame>
    <description>Percentage of subjects with complete response (CR) and partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per local assessment</measure>
    <time_frame>Duration of study approximately 25 months</time_frame>
    <description>Time from first radiographic evidence of response assessed based on local radiologist/investigator review to the earliest documented PD or death due to underlying disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per central assessment</measure>
    <time_frame>Duration of study approximately 25 months</time_frame>
    <description>Time from first radiographic evidence of response review to the earliest documented PD or death due to underlying disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) per local review</measure>
    <time_frame>Duration of study approximately 25 months</time_frame>
    <description>Time from first dose until first documented radiographic evidence of response of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) per central review</measure>
    <time_frame>Duration of study approximately 25 months</time_frame>
    <description>Time from first dose until first documented radiographic evidence of response of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of Free Survival (PFS) per local review</measure>
    <time_frame>Duration of study approximately 25 months</time_frame>
    <description>Time from first dose to the earliest documented date of disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of Free Survival (PFS) per central review</measure>
    <time_frame>Duration of study approximately 25 months</time_frame>
    <description>Time from first dose to the earliest documented date of disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Duration of study approximately 25 months</time_frame>
    <description>Time from first dose to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety through the incidence of adverse events</measure>
    <time_frame>Duration of study approximately 25 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of encorafenib</measure>
    <time_frame>2 hours and 6 hours after dose on Day 1 cycle 1; Predose and 2 hours post dose on Day 1 cycle 2 (cycle length = 28 days)</time_frame>
    <description>Plasma concentration of encorafenib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of binimetinib</measure>
    <time_frame>2 hours and 6 hours after dose on Day 1 cycle 1; Predose and 2 hours post dose on Day 1 cycle 2 (cycle length = 28 days)</time_frame>
    <description>Plasma concentration of binimetinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of cetuximab</measure>
    <time_frame>2 hours and 6 hours after dose on Day 1 cycle 1; Predose and 2 hours post dose on Day 1 cycle 2 (cycle length = 28 days)</time_frame>
    <description>Plasma concentration of cetuximab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Quality of Life from Baseline to end of the study</measure>
    <time_frame>At screening, at Cycle 1 Day 1 and at the end of the study (each cycle is 28 days)</time_frame>
    <description>Change in the Quality of Life Questionnaire for Cancer subjects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>BRAF V600E-mutant Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>encorafenib plus binimetinib plus cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>encorafenib</intervention_name>
    <description>Once daily, orally</description>
    <arm_group_label>1 Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Binimetinib</intervention_name>
    <description>Twice daily, orally</description>
    <arm_group_label>1 Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Standard of care for the 28 first weeks and then every 2 weeks</description>
    <arm_group_label>1 Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥ 18 years of age&#xD;
&#xD;
          -  Histologically or cytologically confirmed CRC that is metastatic&#xD;
&#xD;
          -  Presence of BRAF V600E in tumor tissue determined by local assay at any time prior to&#xD;
             screening and confirmed by central laboratory&#xD;
&#xD;
          -  Evidence of measurable disease as per RECIST, v1.1&#xD;
&#xD;
          -  Subject able to receive cetuximab as per approved label with regards to RAS status&#xD;
&#xD;
          -  ECOG Status 0 or 1&#xD;
&#xD;
          -  Adequate renal, hepatic, cardiac and bone marrow functions and adequate electrolytes&#xD;
             as per protocol&#xD;
&#xD;
          -  Subject able to take oral medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic therapy for metastatic disease&#xD;
&#xD;
          -  Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab or other anti-EGFR&#xD;
             inhibitors&#xD;
&#xD;
          -  Symptomatic brain metastasis or Leptomeningeal disease&#xD;
&#xD;
          -  History or current evidence of Retinal Vein Occlusion (RVO) or current risk factors&#xD;
             for RVO&#xD;
&#xD;
          -  History of chronic inflammatory bowel disease or Crohn's disease requiring medical&#xD;
             intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12&#xD;
             months prior to first dose.&#xD;
&#xD;
          -  Impaired cardiovascular function or clinically significant cardiovascular diseases:&#xD;
             history of myocardial infarction or coronary disorders within 6 months prior to start&#xD;
             of study treatment, symptomatic congestive heart failure (grade 2 or higher), past or&#xD;
             current clinically significant arrhythmia and/or conduction disorder within 6 months&#xD;
             prior to study treatment start&#xD;
&#xD;
          -  History of thromboembolic or cerebrovascular events within 6 months prior to start of&#xD;
             study treatment&#xD;
&#xD;
          -  Concurrent neuromuscular disorder that is associated with potential elevation of&#xD;
             Creatine Kinase&#xD;
&#xD;
          -  Known contraindication to cetuximab administration as per SPC/approved label&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle KLAUCK, MD</last_name>
    <role>Study Director</role>
    <affiliation>Corporate Medical&amp;Patient/Consumer Division, Pierre Fabre Medicament</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PC dba West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Wien</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent, Gastro-Enterology</name>
      <address>
        <city>Gent</city>
        <state>East Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trial DIO, UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM- VAL d 'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <state>Cedex 5</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan CHRU de Brest Institut de cancérologie et d'hematologie</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM CHU Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin Gastroenterology</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPITAL HAUT-LEVEQUE, Av de MAGELLAN</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO- Site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU TOULOUSE Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Forlì-Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia IRCC Candiolo</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinic San Martin</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.M. Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre Fabre Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre Fabre Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre Fabre Investigative Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre Fabre Investigative Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre Fabre Investigative Site</name>
      <address>
        <city>Nagaizumi-cho</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre Fabre Investigative Site</name>
      <address>
        <city>Koto-ku,</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Antonius Ziekenhuis</name>
      <address>
        <city>Utrecht</city>
        <zip>3543 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <state>Community Of Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario De Navarra S Oncologia Medica</name>
      <address>
        <city>Pamplona</city>
        <state>Navarre</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia (ICO L'Hospitalet)</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Santa Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La FE</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital, Lowes Bridge</name>
      <address>
        <city>Torquay</city>
        <state>Devon</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI research team, OHCT, Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Research Team, The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

